Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 57

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 57
---
 | ​ | ​                     | ​ | 237,276 | ​ | ​ | ​ | ​         | ​ | 329,276 | ​ | ​ |
| Joseph Patti           | ​ | ​ | ​                             | ​ | 66,000 | ​ | ​ | ​ | ​                     | ​ | 237,276 | ​ | ​ | ​ | ​         | ​ | 303,276 | ​ | ​ |
| Todd Peterson          | ​ | ​ | ​                             | ​ | 53,000 | ​ | ​ | ​ | ​                     | ​ | 237,276 | ​ | ​ | ​ | ​         | ​ | 290,276 | ​ | ​ |
| Sarah J. Schlesinger   | ​ | ​ | ​                             | ​ | 54,000 | ​ | ​ | ​ | ​                     | ​ | 237,276 | ​ | ​ | ​ | ​         | ​ | 291,276 | ​ | ​ |

(1) In accordance with SEC rules, this column represents the aggregate grant date fair value of the option awards granted during 2024 computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in Note 10 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. (2) In addition to the annual option grant with a grant date fair value of approximately $138,602 for 2024, each non-employee director received a make-whole grant in March 2024 to make them whole for an error in the amount of their 2023 option grant. In December 2023, each non-employee director was granted an option to purchase 10,461 shares of our common stock subject to vesting based on the director’s continuous service as of immediately prior to our 2024 Annual Meeting. Subsequent to the grant, it was discovered that an inadvertent calculation error resulted in each non-employee director receiving substantially fewer options than was intended to be granted in respect of services during 2023 (which was intended to be a number of options with a grant date fair value of approximately $120,000). To rectify this error, each non-employee director was granted a make-whole option to purchase an additional 39,666 shares of our common stock in March 2024 that is also subject to vesting based